Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Primary tumor volume measurements in Ewing sarcoma: MRI inter- and intraobserver variability and comparison with FDG-PET
Published in: ACTA ONCOLOGICA
Access to document
10.1080/0284186X.2017.1398411
document
BACKGROUND: Primary tumor volume is as an important and independent prognostic factor in Ewing sarcoma. However, the observer variability of magnetic resonance imaging (MRI)-based primary tumor volume measurements in newly diagnosed Ewing sarcoma has never been investigated. Furthermore, it is unclear how MRI-based volume measurements compare to (18)F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)-based volume measurements. This study aimed to determine the observer variability of simplified MRI-based primary tumor volume measurements in newly diagnosed treatment-naive Ewing sarcoma and to compare them to the actual primary tumor volume at MRI...
Somatostatin receptor based hybrid imaging in sarcoidosis
Published in: European Journal of Hybrid Imaging
Access to document
10.1186/s41824-017-0014-y
document
Several diagnostic imaging methodologies are available for the clinical evaluation of sarcoidosis, but all have their limitations. FDG PET/CT is frequently used, but this technique does not provide optimal results in all cases. Novel radiopharmaceuticals aimed at other disease targets may be helpful, particularly in cardiac sarcoidosis when FDG PET/CT has a low diagnostic accuracy, due to difficulties in preparing the patients who should use a specific diet combined with prolonged fasting. 68Ga-labeled somatostatin based receptor hybrid imaging is a potential alternative to FDG PET/CT. This short communication...
Riemer H J A Slart, Klaas-Pieter Koopmans, Peter Paul van Geel, Henk Kramer, Harry J M Groen, C Tji-Joong Gan, Niek H J Prakken, Andor W J M Glaudemans, George D Nossent
Investigation into cardiac sympathetic innervation during the commencement of haemodialysis in patients with chronic kidney disease
Published in: European Radiology Experimental
Access to document
10.1186/s41747-017-0027-0
document
Background: Patients with chronic kidney disease (CKD) who undergo chronic haemodialysis (HD) show altered sympathetic tone, which is related to a higher cardiovascular mortality. The purpose of this study was to investigate the effect of transition from pre-HD to HD on cardiac sympathetic innervation. Methods: Eighteen patients aged 58 ± 18 years (mean ± standard deviation [SD]), 13 males and five females, with stage 5 CKD and nine healthy control subjects aged 52 ± 17 (mean ± SD), three males and six females, were included in this prospective study between May 2010 and December 2013. All...
Walter Noordzij, Akin Özyilmaz, Andor W J M Glaudemans, René A Tio, Esther R Goet, Casper F M Franssen, Riemer H J A Slart
Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.117.193649
document
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment. Whole-body imaging can provide information across lesions within a patient. ER expression in tumor lesions can be visualized by F-18-fluoroestradiol (F-18-FES) PET, and AR expression has been visualized in prostate cancer patients with F-18-fluorodihydrotestosterone (F-18-FDHT) PET. Our aim was to assess the concordance between F-18-FDHT and F-18-FES PET and tumor AR and ER expression measured immunohistochemically in patients with...
Clasina M. Venema, Lemonitsa H. Mammatas, Carolina P. Schröder, Michel van Kruchten, Giulia Apollonio, Andor W. J. M. Glaudemans, Alfons H. H. Bongaerts, Otto S. Hoekstra, Henk M. W. Verheul, Epi Boven, Bert van der Vegt, Erik F. J. de Vries, Elisabeth G. E. de Vries, Ronald Boellaard, Catharina W. Menke van der Houven van Oordt, Geke A. P. Hospers
In vivo quantification of ERβ expression by pharmacokinetic modeling: Studies with 18F-FHNP PET
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.117.192666
document
The estrogen receptor (ER) is a target for endocrine therapy in breast cancer patients. Individual quantification of ER alpha and ER beta expression, rather than total ER levels, might enable better prediction of the response to treatment. We recently developed the tracer 2-F-18-fluoro-6-(6-hydroxynaphthalen-2-yl) pyridin-3-ol (F-18-FHNP) for assessment of ER beta levels with PET. In the current study, we investigated several pharmacokinetic analysis methods to quantify changes in ER beta availability with F-18-FHNP PET. Methods: Male nude rats were subcutaneously inoculated in the shoulder with ER alpha/ER beta-expressing SKOV3...